Evidence map›Paper›PMID 36578048›Full record

ArticleClinical epigenetics2022

Maintenance of methylation profile in imprinting control regions in human induced pluripotent stem cells.

A Pham, C Selenou, E Giabicani, V Fontaine, S Marteau, F Brioude, L David, D Mitanchez, M L Sobrier, I Netchine

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. TET3 protects theiScience · 2025
    Article
  4. Why are imprints unstable in pluripotent stem cells?Biochemical Society transactions · 2025
    Article
  5. Review
  6. Stem cell models of Angelman syndrome.Frontiers in cell and developmental biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

A Pham *INSERM, Centre de recherche Saint Antoine, Sorbonne Université, 75012, Paris, France.
C Selenou *INSERM, Centre de recherche Saint Antoine, Sorbonne Université, 75012, Paris, France.
E GiabicaniINSERM, Centre de recherche Saint Antoine, Sorbonne Université, 75012, Paris, France.
V FontaineInstitut de Cardiométabolisme et Nutrition, Sorbonne Université, 75013, Paris, France.
S MarteauInstitut de Cardiométabolisme et Nutrition, Sorbonne Université, 75013, Paris, France.
F BrioudeINSERM, Centre de recherche Saint Antoine, Sorbonne Université, 75012, Paris, France.
L DavidCHU Nantes, Inserm, CR2TI, Université de Nantes, 44000, Nantes, France.
D MitanchezINSERM, Centre de recherche Saint Antoine, Sorbonne Université, 75012, Paris, France.
M L Sobrier *INSERM, Centre de recherche Saint Antoine, Sorbonne Université, 75012, Paris, France.
I Netchine *INSERM, Centre de recherche Saint Antoine, Sorbonne Université, 75012, Paris, France. irene.netchine@aphp.fr.
Inserm · FRSorbonne Université · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParental imprinting is an epigenetic mechanism that leads to monoallelic expression of a subset of genes depending on their parental origin. Imprinting disorders (IDs), caused by disturbances of imprinted genes, are a set of rare congenital diseases that mainly affect growth, metabolism and development. To date, there is no accurate model to study the physiopathology of IDs or test therapeutic strategies. Human induced pluripotent stem cells (iPSCs) are a promising cellular approach to model human diseases and complex genetic disorders. However, aberrant hypermethylation of imprinting control regions (ICRs) may appear during the reprogramming process and subsequent culture of iPSCs. Therefore, we tested various conditions of reprogramming and culture of iPSCs and performed an extensive analysis of methylation marks at the ICRs to develop a cellular model that can be used to study IDs.

resultsWe assessed the methylation levels at seven imprinted loci in iPSCs before differentiation, at various passages of cell culture, and during chondrogenic differentiation. Abnormal methylation levels were found, with hypermethylation at 11p15 H19/IGF2:IG-DMR and 14q32 MEG3/DLK1:IG-DMR, independently of the reprogramming method and cells of origin. Hypermethylation at these two loci led to the loss of parental imprinting (LOI), with biallelic expression of the imprinted genes IGF2 and DLK1, respectively. The epiPS™ culture medium combined with culturing of the cells under hypoxic conditions prevented hypermethylation at H19/IGF2:IG-DMR (ICR1) and MEG3/DLK1:IG-DMR, as well as at other imprinted loci, while preserving the proliferation and pluripotency qualities of these iPSCs.

conclusionsAn extensive and quantitative analysis of methylation levels of ICRs in iPSCs showed hypermethylation of certain ICRs in human iPSCs, especially paternally methylated ICRs, and subsequent LOI of certain imprinted genes. The epiPS™ culture medium and culturing of the cells under hypoxic conditions prevented hypermethylation of ICRs in iPSCs. We demonstrated that the reprogramming and culture in epiPS™ medium allow the generation of control iPSCs lines with a balanced methylation and ID patient iPSCs lines with unbalanced methylation. Human iPSCs are therefore a promising cellular model to study the physiopathology of IDs and test therapies in tissues of interest.

Indexed as

Induced Pluripotent Stem CellsRNA, Long NoncodingDNA MethylationEpigenesis, GeneticGenomic ImprintingHumansRNA, Long NoncodingChondrogenic differentiationImprinting disordersInduced pluripotent stem cellsMethylationParental imprintingSilver–Russell syndromeTemple syndrome

Identifiers

PMID36578048
PMCPMC9798676
OpenAlexW4313204077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.